Symrise AG (Holzminden, Germany) and Aplantex Bio (Boucherville, Que., Canada) have agreed on a partnership covering new technologies for accessing plant-based molecules as raw material once the molecules of interest have been developed and produced by Aplantex.
“We are intrigued by the potential of Aplantex’s innovative green biotechnology process to help us in securing potential access to hard-to-source plant-based molecules in the context of the significant impacts of climate change,” underlines Dr. Jakob Ley, director of Biobased Ingredients Research at Symrise. Aplantex has been, since 2024, diligently involved in the research & development work to produce the initial molecule of interest requested by Symrise.
“Having already validated our process with the production of Apigenin, Orientin, Vitexin, and Luteolin, four molecules recognized for their antioxidant, anti-inflammatory, antimicrobial, and anti-aging properties, we were able to reach several milestones of Symrise’s validation protocol in record time. We are excited by this significant commercial opportunity, confident about our ability to meet Symrise’s remaining milestones promptly, and aim to provide Symrise with additional hard-to-source molecules in the near future,” concludes Mr. Patrick Charest, B. Sc., P.Eng., mMBA, and CEO of Aplantex.